Sickle Cell Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 55+ Companies and 60+ Therapies | DelveInsight

DelveInsight's "Sickle Cell Disease Pipeline Insights 2025" report provides comprehensive insights about 55+ companies and 60+ drugs in the Sickle Cell Disease Competitive landscape. It covers the Sickle Cell Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Sickle Cell Disease Treatment Landscape. Click here to read more @ Sickle Cell Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Sickle Cell Disease Pipeline Report

* In June 2025, Novo Nordisk A/S announced a study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance.
* In June 2025, CSL Behring conducted a study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerability of CSL889 in study participants.
* In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
* In April 2025, Novartis Pharmaceuticals conducted a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
* In April 2025, Novo Nordisk A/S organized a study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance.
* DelveInsight's Sickle Cell Disease pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Sickle Cell Disease treatment.
* The leading Sickle Cell Disease Companies such as Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics and others.
* Promising Sickle Cell Disease Pipeline Therapies such as Siplizumab, Daratumumab, Alemtuzumab, Sirolimus, ITU512, BEAM-101, Crizanlizumab, Etavopivat, Epeleuton, Voxelotor and others.

Stay informed about the cutting-edge advancements in Sickle Cell Disease Treatments. Download for updates and be a part of the revolution in Genetic Disorders Care @ Sickle Cell Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Sickle Cell Disease Marketed Therapies

* Vertex Pharmaceuticals: CASGEVY

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

CASGEVY Trademark is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for certain indications in multiple jurisdictions for eligible patients.

* Emmaus Medical Inc.: ENDARI

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company is engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases. The initial efforts have focused on treatments for Sickle Cell Disease, a genetic disorder. Emmaus's lead commercial product is Endari Registered , an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

ENDARI [L-glutamine oral powder] is indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. ENDARI is an amino acid indicated to reduce the acute complication of sickle cell disease in adult. The mechanism of action of the amino acid L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive events associated with SCD. The pyridine nucleotides, NAD+ and its reduced form NADH, play roles in regulating and preventing oxidative damage in RBCs. L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of reduced glutathione.

The Sickle Cell Disease Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sickle Cell Disease Treatment.
* Sickle Cell Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sickle Cell Disease market.

Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:

* RL 101: BRL Medicine
* ORY-300:1 Oryzon Genomics
* GSK 4172239D: GlaxoSmithKline
* AG-946: Agios Pharmaceuticals
* BEAM-101: Beam Therapeutics Inc.
* Nula-cel: Graphite Bio
* RG 6107: Roche
* Isoquercetin: Quercis Pharma
* Renizgamglogene autogedtemcel: Editas Medicin
* Inclacumab: Pfizer
* L-glutamine: Emmaus Medical, Inc
* CASGEVY: Vertex Pharmaceuticals
* ESCAPE: Beam Therapeutic
* IHP-102: IHP Therapeutics
* HBI-002: Hillhurst Biopharmaceuticals
* BEAM101: Beam Therapeutics
* EPI01: Novo Nordisk
* VIT-2763: CSL Vifor
* Inclacumab: Pfizer
* L-glutamine: Emmaus Medical
* Oxbryta: Pfizer
* Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals
* Mitapivat: Agios Pharmaceuticals
* Canakinumab: Novartis
* ALXN1820: Alexion Pharmaceuticals
* Crovalimab: Chugai Pharmaceutical/Roche
* EDIT 301: Editas Medicine
* BIVV003: Sangamo Therapeutics
* BEAM101: Beam Therapeutics
* Hemopexin: CSL Behring

Get a detailed analysis of the latest innovations in the Sickle Cell Disease pipeline. Explore DelveInsight's expert-driven report today! @ Sickle Cell Disease Unmet Needs [https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Sickle Cell Disease Companies

Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics, and others.

Sickle Cell Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

- Intranasal

- Intrathecal

- Intravenous

- Oral

- Oral/Intravenous

- Parenteral

- Subcutaneous

- Subcutaneous/Intramuscular

- Transdermal

Sickle Cell Disease Products have been categorized under various Molecule types, such as

- Antisense oligonucleotide

- Gene therapy

- Hormones

- Neuropeptides

- Oligonucleotides

- Small Molecule

- Triglyceride

Discover the latest advancements in Sickle Cell Disease Treatment by visiting our website. Stay informed about how we're transforming the future of Genetic Disorders @ Sickle Cell Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Sickle Cell Disease Pipeline Report

* Coverage- Global
* Sickle Cell Disease Companies- Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics and others.
* Sickle Cell Disease Pipeline Therapies- Siplizumab, Daratumumab, Alemtuzumab, Sirolimus, ITU512, BEAM-101, Crizanlizumab, Etavopivat, Epeleuton, Voxelotor and others.
* Sickle Cell Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sickle Cell Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Sickle Cell Disease Pipeline on our website @ Sickle Cell Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Sickle Cell Disease (SCD): Overview
* Sickle Cell Disease -Analytical Perspective: In-depth Commercial Assessment
* Competitive Landscape
* Sickle Cell Disease: Company and Product Profiles (Marketed Therapies)
* Vertex Pharmaceuticals
* CASGEVY
* Sickle Cell Disease: Company and Product Profiles (Pipeline Therapies)
* Late Stage Products (Phase III)
* Pfizer
* Inclacumab
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Roche
* RG 6107
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Beam Therapeutics
* BEAM-101
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* BRL Medicine
* BRL 101
* Drug profiles in the detailed report.....
* Inactive Products
* Sickle Cell Disease- Unmet needs
* Sickle Cell Disease - Market drivers and barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sickle-cell-disease-clinical-trial-analysis-key-insights-into-rich-pipeline-featuring-55-companies-and-60-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.